Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
CK20 was more sensitive for the diagnosis of bladder urothelial carcinoma (BUC) than all types of BC (0.83 vs 0.75).
|
29931834 |
2019 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, it has been suggested that the immunohistochemical expressions of only two markers, luminal (CK20+, CK5/6-) and basal (CK5/6+, CK20-), is sufficient to identify the molecular subtypes of bladder cancer.
|
31240474 |
2019 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
At least two markers (MRE11 and CK20) were significantly associated with survival in patients with bladder cancer, and a further three markers showed results warranting expert follow-up.
|
29991697 |
2018 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We investigated mRNA expression of KRT5 and KRT20 and its predictive value in stage pT1 bladder cancer.
|
28074276 |
2017 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biomarkers, including p53, Ki-67, and CK20, with classic and prognostic factors with recurrence and novel markers such as EN2 may provide a more accurate prediction of outcome compared with any single marker, improving risk stratification and clinical management of patients with BCa.
|
26574637 |
2017 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of CK20 mRNA as confirmed marker of bladder cancer was also assayed.
|
28888400 |
2017 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Transcript levels of IGF2 and CK20 enabled the detection of BCa with a diagnostic performance similar to VUC.
|
28484844 |
2017 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CK20 expression in non-umbrella cells is a robust marker of urinary bladder carcinoma.
|
28940433 |
2017 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, the sensitivity and specificity of combined detection with CK20 and FGFR1 for the differentiation between invasive and non-invasive stages of bladder cancer reached 97.5% and 92.5%, respectively.
|
27259667 |
2016 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Quantitative assessment of tumor-related transcript markers, particularly of CK20, may serve as a noninvasive method to identify patients with BCa.
|
26328914 |
2016 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of cytokeratin 20 was always significantly higher in patients with bladder cancer when compared with that in both the tumor-free groups.
|
26282902 |
2015 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
CK20-positive cells were detected in 16 of 51 (31.4%) BCa patients of all stages.
|
21190793 |
2011 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the current study, we describe the isolation and characterization of a tumor-initiating cell (T-IC) subpopulation in primary human bladder cancer, based on the expression of markers similar to that of normal bladder basal cells (Lineage-CD44(+)CK5(+)CK20(-)).
|
19666525 |
2009 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine.
|
18026991 |
2008 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer.
|
18804101 |
2008 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Dysregulation of CK20 expression is an early event in the carcinogenesis of papillary noninvasive bladder cancer, but occurs later than FGFR3 mutations.
|
17240035 |
2007 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymph node CK 20 RT-PCR correlates with pathological stage in bladder cancer.
|
16475726 |
2006 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, four of the differentially expressed genes in microarrays related to bladder cancer (KRT20, IGF2, GSN, and CCL2) were analyzed in 36 tumoural and 14 control BW samples by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR).
|
16815626 |
2006 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
|
15245962 |
2004 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
For control purposes, CK-20 expression was examined in cells of 1) bladder carcinoma tumors of 5 patients, 2) blood of either patients with bladder carcinoma (n = 5) or healthy controls (n = 5), and 3) three different cell lines.
|
9445193 |
1998 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The reverse transcriptase polymerase chain reaction method was used to determine expression of CK-20 in cells separated from urine of patients with bladder carcinoma.
|
9817302 |
1998 |